Literature DB >> 14576822

Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.

Chunyan Zhao1, Eric W-F Lam, Andrew Sunters, Eva Enmark, Manuela Tamburo De Bella, R Charles Coombes, Jan-Ake Gustafsson, Karin Dahlman-Wright.   

Abstract

Two novel estrogen receptor beta (ERbeta) mRNA isoforms that diverge in their 5'-untranslated regions, ERbeta mRNA (0K-1) and ERbeta mRNA (0N-1), have recently been identified. This indicates that transcription of the human ERbeta gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ERbeta isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ERbeta promoters is involved in regulation of ERbeta gene expression. Using quantitative real-time PCR techniques, we found that ERbeta mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ERbeta gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ERbeta mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ERbeta mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ERbeta mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ERbeta mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ERbeta gene silencing in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576822     DOI: 10.1038/sj.onc.1207100

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

Review 1.  Epigenetic effects of endocrine-disrupting chemicals on female reproduction: an ovarian perspective.

Authors:  Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Front Neuroendocrinol       Date:  2010-07-04       Impact factor: 8.606

2.  Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity.

Authors:  Jianguo Wu; Xiang Ling; Dalin Pan; Pasha Apontes; Lei Song; Ping Liang; Dario C Altieri; Terry Beerman; Fengzhi Li
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

3.  Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation.

Authors:  Abeer M Mahmoud; Umaima Al-Alem; Mohamed M Ali; Maarten C Bosland
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-27       Impact factor: 4.292

4.  Estrogen receptor-alpha methylation predicts melanoma progression.

Authors:  Takuji Mori; Steve R Martinez; Steven J O'Day; Donald L Morton; Naoyuki Umetani; Minoru Kitago; Atsushi Tanemura; Sandy L Nguyen; Andy N Tran; He-Jing Wang; Dave S B Hoon
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

5.  Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.

Authors:  Matthew P Goetz; Daniel J Schaid; D Lawrence Wickerham; Stephanie Safgren; Taisei Mushiroda; Michiaki Kubo; Anthony Batzler; Joseph P Costantino; Victor G Vogel; Soonmyung Paik; Erin E Carlson; David A Flockhart; Norman Wolmark; Yusuke Nakamura; Richard M Weinshilboum; James N Ingle; Matthew M Ames
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

6.  Reduced levels of oestrogen receptor beta mRNA in Swedish patients with chronic fatigue syndrome.

Authors:  Hanna Gräns; Maria Nilsson; Karin Dahlman-Wright; Birgitta Evengård
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

7.  Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.

Authors:  Zinovia Kefalopoulou; Vassiliki Tzelepi; Vassiliki Zolota; Petros D Grivas; Christos Christopoulos; Haralabos Kalofonos; Theodoros Maraziotis; Georgia Sotiropoulou-Bonikou
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

8.  Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report.

Authors:  Xavier Tekpli; Vidar Skaug; Rita Bæra; David H Phillips; Aage Haugen; Steen Mollerup
Journal:  Cell Oncol (Dordr)       Date:  2016-08-29       Impact factor: 6.730

9.  Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor beta on mRNA stability and translatability.

Authors:  Milica Putnik; Chunyan Zhao; Jan-Ake Gustafsson; Karin Dahlman-Wright
Journal:  BMC Genet       Date:  2009-09-15       Impact factor: 2.797

Review 10.  Probing the link between oestrogen receptors and oesophageal cancer.

Authors:  Farhan Rashid; Raheela N Khan; Syed Y Iftikhar
Journal:  World J Surg Oncol       Date:  2010-02-10       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.